A Novel Statistical Prognostic Score Model That Includes Serum CXCL5 Levels and Clinical Classification Predicts Risk of Disease Progression and Survival of Nasopharyngeal Carcinoma Patients

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Zhang, Haibo ^a   Xia, Weixiong ^a   Lu, Xing ^a   Sun, Rui ^a   Wang, Lin ^a   Zheng, Lisheng ^a   Ye, Yanfang ^a   Bao, Yingna ^a   Xiang, Yanqun ^a   Guo, Xiang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; STATISTICAL MODEL; SURVIVAL TIME; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; CHEMOKINE CXCL5; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK; YOUNG ADULT;

EID: 84874556405     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057830     Document Type: Article

References (30)

1. Wei WI, Sham JS, (2005) Nasopharyngeal carcinoma. Lancet 365: 2041-2054.
2. Fang CY, Lee CH, Wu CC, Chang YT, Yu SL, et al. (2009) Recurrent chemical reactivations of EBV promotes genome instability and enhances tumor progression of nasopharyngeal carcinoma cells. Int J Cancer 124: 2016-2025.
3. Endo K, Kondo S, Shackleford J, Horikawa T, Kitagawa N, et al. (2009) Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration. Oncogene 28: 1725-1735.
4. Lee AWM, Lau WH, Tung SY, Chua DTT, Chappell R, et al. (2005) Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23: 6966-6975.
5. Lai SZ, Li WF, Chen L, Luo W, Chen YY, et al. (2011) How Does Intensity-Modulated Radiotherapy Versus Conventional Two-Dimensional Radiotherapy Influence the Treatment Results in Nasopharyngeal Carcinoma Patients?. Int J Radiat Oncol Biol Phys 80: 661-668.
6. Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, et al. (2001) Long-Term Results of a Prospective Randomized Trial Comparing Neoadjuvant Chemotherapy Plus Radiotherapy with Radiotherapy Alone for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. Ai Zheng 20: 505-510.
7. Lee AWM, Sze WM, Au JSK, Leung SF, Leung TW, et al. (2005) Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. Int J Radiat Oncol Biol Phys 61: 1107-1116.
8. Lu X, Qian CN, Mu YG, Li NW, Li S, et al. (2011) Serum CCL2 and serum TNF-α - Two new biomarkers predict bone invasion, post-treatment distant metastasis and poor overall survival in nasopharyngeal carcinoma. Eur J Cancer 47: 339-346.
9. Xu J, Wan XB, Huang XF, Chan KCA, Hong MH, et al. (2010) Serologic Antienzyme Rate of Epstein-Barr Virus DNase-Specific Neutralizing Antibody Segregates TNM Classification in Nasopharyngeal Carcinoma. J Clin Onco l28: 5202-5209.
10. Mao YP, Li WF, Chen L, Sun Y, Liu LZ, et al. (2009) A clinical verification of the Chinese 2008 staging system for nasopharyngeal carcinoma. Ai Zheng 28: 1022-1028.
11. Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, et al. (1991) Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med 174: 1355-1362.
12. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, et al. (1994) Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 94: 1012-1018.
13. Kuo PL, Chen YH, Chen TC, Shen KH, Hsu YL, (2011) CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway. J Cell Physiol 226: 1224-1231.
14. Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, et al. (2006) Down-regulation of CXCL5 Inhibits Squamous Carcinogenesis. Cancer Res 66: 4279-4284.
15. Kawamura M, Toiyama Y, Tanaka K, Saigusa S, Okugawa Y, et al. (2011) CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer 48: 2244-2251.
16. Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, et al. (2012) Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology: in press.
17. Li A, King J, Moro A, Sugi MD, Dawson DW, et al. (2011) Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol 178: 1340-1349.
18. Park JY, Park KH, Bang S, Kim MH, Lee JE, et al. (2007) CXCL5 overexpression is associated with late classification gastric cancer. J Cancer Res Clin Oncol 133: 835-840.
19. Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, et al. (2008) CXCL5 promotes prostate cancer progression. Neoplasia (New York, NY) 10: 244.
20. Baier PK, Eggstein S, Wolff-Vorbeck G, Baumgartner U, Hopt UT, (2005) Chemokines in human colorectal carcinoma. Anticancer Res 25: 3581-3584.
21. Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, et al. (2006) ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Therapeut 112: 139-149.
22. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, et al. (2005) The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 175: 5351.
23. Fregene T, Khanuja P, Noto A, Gehani S, Van Egmont E, et al. (1993) Tumor-associated angiogenesis in prostate cancer. Anticancer Res 13: 2377.
24. Samoszuk M, Lin F, Rim P, Strathearn G, (1996) New marker for blood vessels in human ovarian and endometrial cancers. Clin Cancer Res 2: 1867-1871.
25. White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, et al. (2003) Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer. Clin Cancer Res 9: 853-860.
26. Ong YK, Heng DM, Chung B, Leong SS, Wee J, et al. (2003) Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur J Cancer 39: 1535-1541.
27. Toh CK, Heng D, Ong YK, Leong SS, Wee J, et al. (2005) Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma. Br J Cancer 92: 1382-1387.
28. Jin Y, Cai XY, Cai YC, Cao Y, Xia Q, et al. (2012) To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area. Eur J Cancer 48: 882-888.
29. Cao X, Luo RZ, He LR, Li Y, Lin WQ, et al. (2011) Prognosticators and Risk Grouping in Patients with Lung Metastasis from Nasopharyngeal Carcinoma: A more accurate and appropriate assessment of prognosis. Radiat Oncol 6: 104.
30. Cheng SH, Tsai SY, Horng CF, Yen KL, Jian JJ, et al. (2006) A prognostic scoring system for locoregional control in nasopharyngeal carcinoma following conformal radiotherapy. Int J Radiat Oncol Biol Phys 66: 992-1003.